Eventide Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Eventide Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,000	Closed	-$1.12M	–	113
2014 Q4	$1.12M	Hold	2,000	–	–	0.12%	96
2014 Q3	$1.05M	Hold	2,000	–	–	0.15%	91
2014 Q2	$1.4M	Sell	2,000 -2,520	-56%	-$1.17M	0.19%	88
2014 Q1	$2.09M	Buy	4,520 +2,547	+129%	+$1.29M	0.33%	65
2013 Q4	$678K	Buy	+1,973	New	+$545K	0.21%	71

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Eventide Asset Management's KPTI Position: Q1 2015 in Review

Eventide Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2015, closing a stake of 2,000 shares — an estimated $1.12M sold.

Eventide Asset Management first reported a position in KPTI in Q4 2013 and held it in 5 quarters. The position peaked at $2.09M in Q1 2014. 85 funds tracked by Wall St. Rank hold KPTI as of Q1 2015.

Eventide Asset Management reported no remaining Karyopharm Therapeutics position as of Q1 2015 after selling out during the quarter.
Eventide Asset Management sold 2,000 Karyopharm Therapeutics shares in Q1 2015, an estimated $1.12M.
Eventide Asset Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 5 quarters.
Eventide Asset Management's Karyopharm Therapeutics position peaked at $2.09M in Q1 2014.
85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2015.

Based on Eventide Asset Management's 13F filing for Q1 2015, filed 14 May 2015.